It has been reported that bemcentinib blocks the catalytic activities of AXL, at nanomolar concentrations (IC50 = 14 nM), reduces AXL and p-AXL levels, induces the accumulation of autophagosomes and lysosomes, blocks lysosomal acidification and recycling, and increases apoptosis of tumor cells [121]. The gene discussed is AXL; the disease is neoplasm.